Levels of MAGOH/MAGOHB expression were positively correlated with malignancy with 93.2% of grade 4 gliomas, 83.3% of grade 3 gliomas, but only 44.4% of grade 2 gliomas (p-value <0.001; displaying MAGOH/MAGOHB expression (Supplementary Table S4). Here, MAGOH is linked to central nervous system cancer.